



ACNE, ROSACEA, AND RELATED DISORDERS (INCLUDING HIDRADENITIS SUPPURATIVA)

## ADALIMUMAB VERSUS RIFAMPICIN PLUS CLINDAMYCIN FOR THE TREATMENT OF MODERATE-TO-SEVERE HIDRADENITIS SUPPURATIVA

C Marasca<sup>(1)</sup> - Mc Annunziata<sup>(2)</sup> - G Fabbrocini<sup>(2)</sup>

University Federico II, Clinical Medicine And Surgery - Section Of Dermatology, Naples, Italy<sup>(1)</sup> - University Federico II, Clinical Medicine And Surgery, Naples, Italy<sup>(2)</sup>

**Introduction:** According to the current guidelines for moderate-to-severe Hidradenitis Suppurativa (HS), Clindamycin 300 mg twice daily plus Rifampicin 600 mg once daily is indicated as the first medical approach. Its inefficacy may get a patient suitable for starting Adalimumab.

**Objective:** The objective is to evaluate the efficacy of the combination Rifampicin and Clindamycin compared to Adalimumab in patients affected by moderate-to-severe HS.

**Materials and Methods:** We conducted a retrospective study regarding 60 consecutive patients affected by HS.

The data collected (Sartorius score -mSS-, Hidradisk, HiSCR) were registered before starting treatment (T0) and after 10 weeks (T10).

Thirty patients conducted a treatment with Clindamycin 300 mg twice daily and Rifampicin 600 mg once daily for 10 weeks; other 30 subjects conducted a therapy with Adalimumab (loading dose: 160 mg at week 0, 80 mg at week 2, 40 mg at week 4, than 40 mg every week). The Mann-Whitney test was used to calculate statistical differences between baseline and week 10.

**Results:** Rifa-Clinda Group (20 females, 10 males): the mean mSS at T0 was 68,8 while the value at T10 was 57,8 (p value = 0,0052). The mean HIDRADisk value at T0 was 74,73 while the value at T10 was 62 (p value = 0,0095). Ten patients achieved the HiSCR.

Adalimumab Group (22 females, 8 males): the mean mSS at T0 was 74,93 while the value at T10 was 39,86 (p value <0,0001). The mean HIDRADisk value before at T0 was 77,73 while the value at T10 was 51,86 (p value < 0,0001). Eighteen patients achieved the HiSCR.

**Conclusions:** In conclusion, we registered better results with Adalimumab compared to antibiotics.

